Bimatoprost is a synthetic prostamide analog primarily acting as a selective prostaglandin F2α (FP) receptor agonist. In vitro, it increases aqueous humor outflow in cultured human trabecular meshwork and ciliary muscle cells, showing dose-dependent elevation of matrix metalloproteinase (MMP) activity at 10–100 nM. In vivo, bimatoprost lowers intraocular pressure (IOP) in ocular hypertensive and normotensive animal models. In rabbits, topical doses of 0.01–0.03% reduced IOP by 25–35% within 5 hours, sustained for 24 hours. In monkeys, 0.03% topical treatment produced a maximal IOP reduction of ~30% over 24 hours. Bimatoprost also promotes eyelash growth in rodents, increasing hair length and density by 20–40% after 4 weeks of daily application. These effects are consistent with its dual role in enhancing uveoscleral outflow and modulating hair follicle activity, supporting its clinical use in glaucoma, ocular hypertension, and hypotrichosis of the eyelashes.